As expected, the approved treatments for FD were well represented in the literature, with 187 studies evaluating ERT with agalsidase alfa and/or agalsidase beta, 30 studies examining migalastat, and 11 studies investigating pegunigalsidase alfa. This evidence concerns the gene GLA and Fabry disease.